+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Molecular Diagnostics Market - Global Forecast 2026-2032- Product Image
Molecular Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Molecular Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305518
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Molecular Diagnostics Market is projected to reach USD 19.61 Billion in 2026. It is expected to continue growing at a CAGR of 9.70%, reaching USD 34.27 Billion by 2032.

Molecular diagnostics is moving from a specialized laboratory discipline to a core pillar of precision medicine, public health surveillance, and biopharma development. Demand is supported by the clinical value of PCR, RT-PCR, digital PCR, next-generation sequencing, liquid biopsy, companion diagnostics, and point-of-care molecular testing across infectious disease, oncology, inherited disease, reproductive health, and antimicrobial resistance management.

Evidence-based demand drivers remain strong. IARC reported nearly 20 million new cancer cases globally in 2022, while the WHO has highlighted tuberculosis, HIV, viral hepatitis, and antimicrobial resistance as persistent priorities requiring accurate and timely testing. For healthcare systems, molecular diagnostics improves early detection, therapy selection, outbreak response, and treatment monitoring, making it a strategic investment area rather than a discretionary laboratory expense.

Transformative Shifts in the Molecular Diagnostics Landscape

The molecular diagnostics landscape is being reshaped by decentralization, automation, syndromic testing, and the shift from single-analyte assays to multiplex and sequencing-based workflows. COVID-19 accelerated molecular testing capacity worldwide, but the longer-term shift is broader: hospitals, reference laboratories, and public health agencies are now applying molecular tools to respiratory infections, sepsis, oncology, transplant monitoring, pharmacogenomics, and rare disease diagnosis.

Regulation is also transforming market behavior. The European Union In Vitro Diagnostic Regulation has raised requirements for clinical evidence and post-market surveillance, while the United States continues to scrutinize laboratory-developed tests and companion diagnostic pathways. These changes favor manufacturers and laboratories with validated assays, scalable quality systems, strong clinical evidence, and integrated informatics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across molecular diagnostics, improving assay design, variant interpretation, quality control, laboratory workflow optimization, and clinical decision support. AI is especially relevant in next-generation sequencing, where algorithms help prioritize variants, interpret complex genomic signatures, and connect molecular findings with evidence-based therapy options.

The impact is not limited to analytics. AI-enabled automation can reduce manual review, support capacity planning, improve sample routing, and detect anomalies in high-throughput laboratories. However, adoption must be governed by transparent validation, cybersecurity, data provenance, bias monitoring, and alignment with evolving oversight frameworks, including FDA activity on AI-enabled medical devices and the EU AI Act.

Key Regional Insights

Asia-Pacific is one of the fastest-evolving molecular diagnostics regions due to expanding hospital networks, rising cancer burden, infectious disease surveillance needs, and investment in genomics across China, India, Japan, South Korea, Australia, and ASEAN markets. National programs supporting tuberculosis testing, viral disease surveillance, cancer screening, and rare disease diagnosis are strengthening demand for PCR, NGS, and decentralized molecular platforms. North America remains the leading innovation and reimbursement reference point, supported by advanced laboratory infrastructure, FDA-cleared and laboratory-developed testing ecosystems, oncology companion diagnostics, public health sequencing, and strong biopharma demand.

Europe is shaped by IVDR implementation, national health technology assessment discipline, established screening programs, and growing use of molecular oncology and antimicrobial resistance testing. Latin America is gaining momentum through private laboratory consolidation, expanding hospital access, and infectious disease testing needs in Brazil, Mexico, and other urban healthcare systems. The Middle East is investing in national genomics, tertiary hospitals, and precision medicine programs, particularly across GCC countries, while Africa’s opportunity is closely tied to tuberculosis, HIV, malaria, emerging pathogen surveillance, outbreak preparedness, and scalable point-of-care molecular diagnostics suited to decentralized care settings.

Key Group Insights

ASEAN demand is expanding as Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines invest in hospital diagnostics, infectious disease preparedness, oncology capacity, and laboratory modernization. The GCC is advancing molecular diagnostics through precision medicine initiatives, tertiary care expansion, premarital and newborn screening programs, and national genome initiatives that support inherited disease, cancer testing, and population health planning.

The European Union is defined by IVDR compliance, cross-border evidence standards, reimbursement scrutiny, and the need for clinically validated assays that can meet post-market performance requirements. BRICS countries combine large patient populations with growing local manufacturing, genomics capacity, and public health priorities in tuberculosis, cancer, and infectious disease surveillance. G7 markets remain the benchmark for high-complexity molecular testing, companion diagnostics, laboratory automation, and advanced reimbursement models, while NATO economies also place strategic value on biosecurity, pathogen surveillance, and resilient diagnostic supply chains.

Key Country Insights

The United States leads in molecular diagnostics innovation through advanced reference laboratories, FDA-cleared assays, oncology NGS, liquid biopsy, newborn screening, and companion diagnostic adoption. Canada benefits from public health laboratory strength, genomics initiatives, and coordinated infectious disease surveillance, while Mexico and Brazil are expanding private diagnostic networks, hospital-based molecular testing, and infectious disease capabilities. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health systems, cancer strategies, antimicrobial resistance priorities, and IVDR-driven evidence requirements, while Russia maintains demand across infectious disease testing, oncology diagnostics, and hospital-based molecular workflows.

China is scaling domestic IVD manufacturing, oncology testing, sequencing capacity, and public health molecular infrastructure, while India is expanding affordable PCR, tuberculosis testing, oncology diagnostics, and decentralized laboratory access under a healthcare system that continues to prioritize infectious disease control and cancer care. Japan and South Korea remain leaders in automation, oncology diagnostics, genomic medicine, and high-quality clinical laboratory standards. Australia benefits from mature reimbursement structures, public health surveillance, established genetic testing pathways, and strong adoption of advanced infectious disease and inherited disease testing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated molecular diagnostics with clear utility in patient management, reimbursement, and workflow efficiency. Assay portfolios should balance high-volume infectious disease testing with higher-value oncology, pharmacogenomics, reproductive health, antimicrobial resistance, and transplant applications, while platforms should support automation, interoperability, sample-to-answer workflows, and scalable menu expansion.

Commercial strategy should align with regional regulation and evidence expectations. Organizations should invest in IVDR readiness, FDA engagement, companion diagnostic partnerships, AI governance, cybersecurity, data privacy, decentralized testing models, and supply chain resilience for reagents and consumables. Laboratories should reduce turnaround time through integrated workflows and build partnerships with hospitals, payers, public health agencies, and biopharma sponsors to demonstrate measurable clinical and operational outcomes.

Research Methodology

This executive summary is based on secondary research from recognized public health, regulatory, clinical, and industry sources, including the WHO, IARC, CDC, FDA, EMA, OECD, World Bank, national health agencies, peer-reviewed medical literature, clinical guideline bodies, and publicly available regulatory documentation. The analysis emphasizes verified demand drivers, disease burden indicators, regulatory developments, technology adoption patterns, and region-specific healthcare infrastructure signals.

Insights were synthesized using a triangulation approach that compares disease burden, installed laboratory capacity, regulatory requirements, reimbursement maturity, procurement behavior, technology readiness, and public health priorities. The methodology prioritizes evidence-backed interpretation over speculative forecasting and is designed to support strategic planning for molecular diagnostics manufacturers, laboratories, investors, and healthcare decision-makers.

Conclusion

Molecular diagnostics is entering a more evidence-driven and digitally enabled phase, where clinical value, regulatory compliance, automation, and data interpretation determine competitive advantage. The field is expanding beyond pandemic-era testing into durable applications across oncology, infectious disease, genetic testing, companion diagnostics, antimicrobial resistance management, and public health surveillance.

Organizations that combine validated assays, AI-supported interpretation, strong quality systems, interoperable platforms, and region-specific access strategies will be best positioned to capture growth opportunities without relying on speculative demand assumptions. As healthcare systems prioritize earlier diagnosis and targeted treatment, molecular diagnostics will remain essential to precision medicine, resilient public health infrastructure, and measurable patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Molecular Diagnostics Market, by Offering
7.1. Introduction
7.2. Instruments
7.3. Reagents & Kits
7.4. Software & Services
8. Molecular Diagnostics Market, by Technology
8.1. Introduction
8.2. Fluorescence In Situ Hybridization
8.3. Mass Spectrometry
8.4. Microarray Analysis
8.5. Next-Generation Sequencing
8.5.1. Exome Sequencing
8.5.2. RNA Sequencing
8.5.3. Targeted Sequencing
8.5.4. Whole Genome Sequencing
8.6. Polymerase Chain Reaction
8.6.1. Digital PCR
8.6.2. Multiplex PCR
8.6.3. Real-Time PCR
9. Molecular Diagnostics Market, by Specimen Type
9.1. Introduction
9.2. Blood
9.3. Cerebrospinal Fluid (CSF)
9.4. Nasal/Throat Swabs
9.5. Saliva
9.6. Stool
9.7. Tissue Biopsies
9.8. Urine
10. Molecular Diagnostics Market, by Test Type
10.1. Introduction
10.2. Point Of Care
10.3. Laboratory Based
11. Molecular Diagnostics Market, by Application
11.1. Introduction
11.2. Genetic Testing
11.2.1. Carrier Testing
11.2.2. Diagnostic Testing
11.2.3. Predictive Testing
11.3. Infectious Disease
11.3.1. Bacterial
11.3.2. Parasitic
11.3.3. Viral
11.4. Oncology
11.4.1. Liquid Biopsy
11.4.2. Minimal Residual Disease
11.4.3. Tissue Biopsy
11.5. Prenatal Testing
11.5.1. Invasive
11.5.2. Non-Invasive
12. Molecular Diagnostics Market, by End User
12.1. Introduction
12.2. Academic & Research Institutes
12.3. Diagnostic Laboratories
12.4. Hospitals & Clinics
13. Molecular Diagnostics Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Molecular Diagnostics Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Molecular Diagnostics Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Italy
15.10. Australia
15.11. South Korea
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories Inc.
17.2. Adaptive Biotechnologies Corporation
17.3. ADT Biotech Co., Ltd.
17.4. Agena Bioscience, Inc.
17.5. AstraZeneca plc
17.6. Becton, Dickinson and Company
17.7. BGI Genomics Co., Ltd.
17.8. Bio-Rad Laboratories, Inc.
17.9. Bio-Techne Corporation
17.10. Biocartis Group NV
17.11. bioMérieux SA
17.12. Bioneer Corporation
17.13. Castle Biosciences, Inc.
17.14. Danaher Corporation
17.15. Diasorin S.p,A.
17.16. Exact Sciences Corporation
17.17. F. Hoffmann-La Roche AG
17.18. Genomadix Inc.
17.19. Grifols S.A.
17.20. Guardant Health, Inc.
17.21. Hologic, Inc.
17.22. Illumina, Inc.
17.23. Laboratory Corporation of America Holdings
17.24. Meridian Bioscience, Inc.
17.25. Myriad Genetics, Inc.
17.26. Oxford Gene Technology by Sysmex Corporation
17.27. QIAGEN N.V.
17.28. Siemens Healthineers AG
17.29. Source BioScience
17.30. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL MICROARRAY ANALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL MICROARRAY ANALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MICROARRAY ANALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL EXOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL EXOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL MULTIPLEX PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL MULTIPLEX PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL MULTIPLEX PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL REAL-TIME PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL REAL-TIME PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL REAL-TIME PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CEREBROSPINAL FLUID (CSF) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL NASAL/THROAT SWABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL NASAL/THROAT SWABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL NASAL/THROAT SWABS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL STOOL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL STOOL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL LABORATORY BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL LABORATORY BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL LABORATORY BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CARRIER TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CARRIER TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CARRIER TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL DIAGNOSTIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL DIAGNOSTIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL DIAGNOSTIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PREDICTIVE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL VIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL MINIMAL RESIDUAL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PRENATAL TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PRENATAL TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL NON-INVASIVE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL NON-INVASIVE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL NON-INVASIVE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 151. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 152. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 153. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 154. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 155. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 156. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 157. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 158. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 159. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 160. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 161. EUROPE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 177. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 189. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 190. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 191. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 192. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 193. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 194. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 195. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 197. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 198. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 199. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 200. AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 202. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 203. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 204. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 205. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 214. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 215. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 217. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 218. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 219. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 220. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 221. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 222. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 224. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 225. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 226. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 227. NATO MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 228. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 230. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 231. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 232. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 233. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 234. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 235. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 236. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 237. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 238. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 239. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 240. G7 MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 255. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 256. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 257. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 258. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 259. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 260. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 261. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 262. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 263. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 264. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 265. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 266. BRICS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 269. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 270. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 271. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 272. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 273. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 274. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 275. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 276. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 277. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 278. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 279. ASEAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 282. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 283. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 284. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 285. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 286. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 287. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 288. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 289. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 290. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 291. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 292. GCC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 293. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 300. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 301. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 302. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 303. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 304. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 305. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 306. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 309. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 310. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 311. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 312. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 313. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 314. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 315. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 316. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 317. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 318. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 319. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 320. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 322. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 323. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 324. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 325. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 326. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 327. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 328. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 329. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 330. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 331. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 332. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 335. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 336. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 337. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 338. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 339. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 340. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 341. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 342. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 343. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 344. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 345. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 346. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY OFFERING, 2017-2032 (USD MILLION)
TABLE 348. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 349. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 350. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2017-2032 (USD MILLION)
TABLE 351. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 352. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 353. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 354. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2017-2032 (USD MILLION)
TABLE 355. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2017-2032 (USD MILLION)
TABLE 356. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 357. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, 2017-2032 (USD MILLION)
TABLE 358. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 359. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 360. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, B

Companies Mentioned

  • Abbott Laboratories Inc.
  • Adaptive Biotechnologies Corporation
  • ADT Biotech Co., Ltd.
  • Agena Bioscience, Inc.
  • AstraZeneca plc
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocartis Group NV
  • bioMérieux SA
  • Bioneer Corporation
  • Castle Biosciences, Inc.
  • Danaher Corporation
  • Diasorin S.p,A.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Genomadix Inc.
  • Grifols S.A.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Meridian Bioscience, Inc.
  • Myriad Genetics, Inc.
  • Oxford Gene Technology by Sysmex Corporation
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • Source BioScience
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 34.27 Billion
Compound Annual Growth Rate9.7%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Molecular Diagnostics Market Industry Trends and Global Forecasts to 2035: Distribution by Test Type, Type of Offering, Type of Sample, Type of Technology, Therapeutic Area, End Users, and Geographical Regions - Product Image

Molecular Diagnostics Market Industry Trends and Global Forecasts to 2035: Distribution by Test Type, Type of Offering, Type of Sample, Type of Technology, Therapeutic Area, End Users, and Geographical Regions

  • Report
  • Global
From
United States Molecular Diagnostics Market Report by Technology, Application, Product, End User, States and Company Analysis 2026-2034 - Product Image

United States Molecular Diagnostics Market Report by Technology, Application, Product, End User, States and Company Analysis 2026-2034

  • Report
  • 200 Pages
  • United States
From
North America Molecular Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

North America Molecular Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 96 Pages
  • North America
From
Molecular Diagnostics - Product Image

Molecular Diagnostics

  • Newsletter
  • 100 Pages
  • Global
AI for Clinical & Molecular Diagnostics Market - Global Forecast 2026-2032 - Product Image

AI for Clinical & Molecular Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.